Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 9
Submit an article Journal homepage
393
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Pretreatment serum soluble interleukin-2 receptor level predicts survival in patients with newly diagnosed follicular lymphoma

Kenji NozakiOsaka University Graduate School of Medicine, Suita, Japan; Correspondence[email protected]
View further author information
,
Hiroyuki SugaharaSumitomo Hospital, Osaka, Japan; View further author information
,
Shuji UedaHyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; View further author information
,
Jun IshikawaOsaka International Cancer Institute, Osaka, Japan; View further author information
,
Shigeo FujiOsaka International Cancer Institute, Osaka, Japan; View further author information
,
Hiroaki MasaieOsaka International Cancer Institute, Osaka, Japan; View further author information
,
Yuma TadaOsaka International Cancer Institute, Osaka, Japan; View further author information
,
Takahiro KarasunoRinku General Medical Center, Izumisano, Japan; View further author information
,
Masato IidaKawasaki Hospital, Kobe, Japan; View further author information
,
Hideki MitsuiOtemae Hospital, Osaka, Japan; View further author information
,
Tsuyoshi KamaeOtemae Hospital, Osaka, Japan; View further author information
,
Norimitsu SaitoOtemae Hospital, Osaka, Japan; View further author information
,
Yasuhiro MoriyamaIkeda City Hospital, Ikeda, Japan; View further author information
,
Manabu KawakamiNippon Life Hospital, Osaka, Japan; View further author information
,
Ruri KatoNippon Life Hospital, Osaka, Japan; View further author information
,
Yoshiki NakaeNippon Life Hospital, Osaka, Japan; View further author information
,
Toru KidaToyonaka Municipal Hospital, Toyonaka, Japan; View further author information
,
Satoru KosugiToyonaka Municipal Hospital, Toyonaka, Japan; View further author information
,
Masashi NakagawaOsaka General Medical Center, Osaka, Japan; View further author information
,
Yozo UchidaMinoh City Hospital, Minoh, JapanView further author information
,
Yasuhiko AzenishiMinoh City Hospital, Minoh, JapanView further author information
,
Ryoto SakaniwaOsaka University Graduate School of Medicine, Suita, Japan; View further author information
,
Tetsuhisa KitamuraOsaka University Graduate School of Medicine, Suita, Japan; ORCID Iconhttp://orcid.org/0000-0003-0107-0580View further author information
ORCID Icon &
Hirohiko ShibayamaOsaka University Graduate School of Medicine, Suita, Japan; ORCID Iconhttp://orcid.org/0000-0003-4014-2815View further author information
ORCID Icon show all
Pages 2113-2121 | Received 13 Mar 2020, Accepted 13 Apr 2020, Published online: 04 May 2020

References

  • Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–276.
  • Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. JCO. 2015;33(23):2516–2522.
  • Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265.
  • Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111–1122.
  • Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128(8):1112–1120.
  • Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. JCO. 2012;30(14):1635–1640.
  • Fuji S, Yamaguchi T, Inoue Y, et al. Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation. Haematologica. 2017;102(7):1258–1265.
  • Goto N, Tsurumi H, Goto H, et al. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol. 2012;91(5):705–714.
  • Kusano Y, Yokoyama M, Terui Y, et al. High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy. Blood Cancer J. 2017; Sep 297(9):e614–e614.
  • Umino K, Fujiwara SI, Ikeda T, et al. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. Hematology. 2017; 22(9):521–526.
  • Prochazka V, Papajik T, Faber E, et al. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era. Leuk Lymphoma. 2014; 55(7):1584–1590.
  • Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37:144–152.
  • Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. JCO. 1999;17(4):1244–1244.
  • Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. JCO. 1997;15(3):1110–1117.
  • Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
  • Bachy E, Seymour JF, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. JCO. 2019;37(31):2815–2824.
  • Yoshida N, Oda M, Kuroda Y, et al. Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS One. 2013;8(11):e78730.
  • Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 1985;135(5):3172–3177.
  • Murakami S. Soluble interleukin-2 receptor in cancer. Front Biosci. 2004;9(1-3):3085–3090.
  • Yasuda N, Lai PK, Ip SH, et al. Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood. 1988;71(4):1021–1026.
  • Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. JCO. 2013;31(26):3272–3278.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.